Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Cardiovascular disease wikipedia , lookup
Coronary artery disease wikipedia , lookup
Jatene procedure wikipedia , lookup
Myocardial infarction wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
Quantium Medical Cardiac Output wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Dextro-Transposition of the great arteries wikipedia , lookup
N-terminal pro-brain natriuretic peptide (NT-pro-BNP) Date of SC final approval: About the Measure Domain: Measure: Definition: Purpose: Sickle Cell Disease: Cardiovascular, Pulmonary, and Renal N-terminal pro-brain natriuretic peptide (NT-pro-BNP) A bioassay to determine an individual’s level of N-terminal pro-brain natriuretic peptide (NT-pro-BNP). N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is released from the right or left ventricle of the heart when it is under pressure stress. Levels of NT-pro-BNP can be used as a screening tool to evaluate an individual’s left ventricular ejection fraction (LVEF). Studies have shown that left ventricular systolic dysfunction is associated with chronic heart failure. Additionally, levels of NT-pro-BNP can be elevated in patients with Sickle Cell Disease. About the Protocol Description of Protocol: Selection Rationale: Specific Instructions: This protocol provides instructions for drawing, processing and storing blood according to the National Health and Nutrition Examination Survey (NHANES) methods. As there are many comparable assays for ascertaining levels of N-terminalpro-brain natriuretic peptide (NT-pro-BNP), the protocol also provides basic guidelines to aid comparability among different studies. The Sickle Cell Disease Cardiovascular, Pulmonary, and Renal Working Group selected NT-pro-BNP measurement because it is a validated, specific, low-burden, non-invasive alternative to echocardiography for differentiating patients with ventricular dysfunction. Additionally, this assay does not require sample extraction and there is no detectable cross reactivity with atrial natriuretic peptide (ANP), Nterminal pro-atrial natriuretic peptide (NT-proANP), brain natriuretic peptide (BNP), or urodilatin. The NHANES instructions for drawing, processing and storing blood provide a standard methodology used successfully for many years to ensure comparable results across study sites. However, the Sickle Cell Disease Working Group 1 (Cardiovascular, Pulmonary, and Renal) notes that certain aspects (e.g., exclusion criteria) of the NHANES protocol are study specific and might not be applicable to all types of studies (e.g., sickle cell disease). Collection of blood samples for the measurement of analytes requires a general determination of whether to use serum or plasma for the assay and also a determination of the type of collection tube to be obtained. For example, if serum is to be used a determination needs to be made as to whether red top or serum gel separator collection tubes are used. While comparable values are obtained for many analytes from either serum or plasma, there may be situations where differences are more pronounced and serum or plasma specific norms will be needed for references. The protocol presented here uses red top/serum separator tubes. At times it may be possible to collect both, but other considerations such as participant burden may be the deciding factor. It is important to match assay type with sample type. Some automated devices may preclude the use of serum, for example, while others may be optimized for it. Investigators should choose methods of collection that match the methods of analysis. This will best be done by communicating with the laboratory where the proposed assays will be performed. They will become an important partner with you in assuring that there is compatibility from collection Version 10 – 10/21/09 N-terminal pro-brain natriuretic peptide (NT-pro-BNP) Date of SC final approval: to assays to interpretation and reporting of levels and results. Protocol Text: Summary of the N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Assay The following is a summary version of the full National Health and Nutrition Examination Survey 2011-2012 protocol. Exclusion Criteria Persons will be excluded from this component if they: • Report that they have hemophilia; or • Report that they have received cancer chemotherapy in the last 4 weeks SP = Sample Person. 1. Do you have hemophilia? 1[] 2[] 7[] 9[] Yes No Refused Don’t Know If the SP answers, "Yes," the SP is excluded from the blood draw. If SP answer "No" or "Don’t Know," blood is drawn from the SP. 2. Have you received cancer chemotherapy in the past four weeks or do you anticipate such therapy in the next four weeks? 1 [ ] Yes 2 [ ] No 7 [ ] Refused 9 [ ] Don’t Know If the SP answers, "Yes," the SP is excluded from the blood draw. If SP answer "No" or "Don’t Know," blood is drawn from the SP. Venipuncture Procedures Editor’s Note: Please review chapter 4 of the Laboratory Procedures Manual from the 2011-2012 National Health and Nutrition Examination Survey for a full description of Phlebotomy procedures. This manual is posted here, and is also available at the NHANES website: 2011-2012 NHANES Laboratory Procedures Manual Venipuncture should generally be performed using the median cubital, cephalic, or basilic veins in the left arm unless this arm is unsuitable. If the veins in the left arm are unsuitable, look for suitable veins on the right arm. If the veins in the antecubital space on both arms are not suitable, then look for veins in the forearm or dorsal side of the hand on the left arm/hand and then the right arm/hand. Version 10 – 10/21/09 N-terminal pro-brain natriuretic peptide (NT-pro-BNP) Date of SC final approval: Recording the Results of the Venipuncture Procedure Immediately after completing the venipuncture, record the results of the blood draw, the reasons for a tube not being drawn according to the protocol, and any comments about the venipuncture. Blood Processing Please review chapter 8 of the Laboratory Procedures Manual from the National Health and Nutrition Examination Survey 2011-2012 for a full description of Blood Processing procedures: 2011-2012 NHANES Laboratory Procedures Manual • • • Allow the blood to clot by setting aside for 30 to 45 minutes at room temperature. Do not clot for more than an hour. Centrifuge the tube at room temperature to separate the serum and aliquot into an appropriate storage tube. Determine if the serum is hemolyzed, turbid, lipemic, or icteric. If so, enter a comment to describe the serum. Laboratory Assay for NT-proBNP NT-proBNP can be measured using a two-step sandwich enzyme-linked immunosorbent assay (ELISA)—in streptavidin coated microtitre plates. The Working Groups notes that there are a number of different reagents and instruments which are appropriate to measure the concentration of NT-proBNP. Once an assay is chosen for a particular study, the Working Group recommends that no changes in the protocol be made over the course of the study. To aid comparability, the Working Group recommends that the investigator record the make and manufacturer of equipment used and the repeatability and coefficients of variation for the assay. Participant: Source: Language of Source: Personnel and Training Required: Reference Ranges “In patients with an LVEF of > 50%, 85% of subjects had an NT-proBNP value below 357 pmol/l (1n (357) = 5.9). This value was used as the upper normal limit in the analyses of sensitivity and specificity. It should be stressed that 357 pmol/l is not a true normal value but a cut off value derived from the present hospital inpatient population.” Adults Centers for Disease Control and Prevention (CDC). Nutritional Biomarkers Branch (NBB). Division of Laboratory Sciences. National Center for Environmental Health. National Health and Nutrition Examination Survey Questionnaire. Laboratory Procedures Manual. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011-2012. Bay, M., Kirk, V., Parner, J., Hassager, C., Nielsen, H., Krogsgaard, K., Trawinski, J., Boesgaard, S., & Aldershvile, J. (2003). NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart; 89:150–154. English A phlebotomist, nursing staff, or other health care professional who is trained to draw blood and laboratory staff who are trained to perform this assay. Version 10 – 10/21/09 N-terminal pro-brain natriuretic peptide (NT-pro-BNP) Date of SC final approval: Equipment Needs: Phlebotomy supplies, centrifuge for serum separation, freezer for sample storage is required. Protocol Type: Bioassay Requirements: Requirements Category Common Data Elements: General References: Required (Yes/No): Major equipment No Specialized training No Specialized requirements for biospecimen collection Average time of greater than 15 minutes in an unaffected individual TBD by PhenX Team No No Machado, R. F., Hildesheim, M., Mendelsohn, L., Remaley, A. T., Kato, G. J., & Gladwin, M. T. (2011). NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease British Journal of Haematology Volume 154, issue 4, pp 512–520. Machado, R. F., Anthi, A., Steinberg, M. H., Bonds, D., Sachdev, V., Kato, G. J., Taveira-DaSilva, A. M., Ballas, S. K., Blackwelder, W., Xu, X., Hunter, L., Barton, B., Waclawiw, M., Castro,O., Gladwin, M. T. for the MSH Investigators (2006). N-Terminal Pro-Brain Natriuretic Peptide Levels and Risk of Death in Sickle Cell Disease JAMA 296 (3):310-318. doi:10.1001/jama.296.3.310. Karl, J., Borgya, A., Gallusser, A., Huber, E., Krueger, K., Rollinger, W. & Schenk, J. (1999). Development of a novel, N-Terminal-proBNP (NT-proBNP) assay with a low detection limit Scand JClin Lab Invest 1999; 59(Suppl230):177-181. Additional Information About the Measure Essential Data: Current Age, Race, Ethnicity Related PhenX Measures: Derived Variables: Keywords/Related Concepts: Heart Valve Function, Pulmonary Hypertension, Blood Pressure None N-terminal pro-brain natriuretic peptide, NT-proBNP, Left Ventricular Ejection Fraction, LVEF, Sickle Cell Disease, SCD, Chronic Heart Failure, Pulmonary hypertension, PH, Biomarkers, Immunoassay Version 10 – 10/21/09